Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intellipharmaceutics International, a company specializing in the research, development and manufacture of novel or generic controlled release and targeted release oral solid dosage drugs, has retained the services of Doll Consulting and its principal David Doll for the commercialization of products in its controlled-release generic drug portfolio and its 505(b)(2) New Drug Application (NDA) portfolio.
Subscribe to our email newsletter
Doll has over 26 years of pharmaceutical industry experience in commercial operations, including his tenure as Impax Laboratories’ executive vice president for commercial operations from 2006 to 2008.
Intellipharmaceutics co-founder and CEO Isa Odidi said the company has four products filed with the FDA for obtaining regulatory approval in the US, and Doll, with his impressive track record in business development and commercialization, is an excellent addition to the team.
Doll said Intellipharmaceutics has exceptional drug formulation and development expertise.
"Given its mature product pipeline both on the generics side and its abuse-resistant Rexista technology platform, it is exciting to be part of the impressive growth story that is emerging here," Doll said.